ClinicalTrials.gg
RecruitingNCT06989385CORALINEUpdated Jan 22, 2026

CORALINE - Correlation Between Physiological and Clinical Variables and Failure of Non-Invasive Respiratory Support in Patients With Acute Respiratory Failure

An observational study in Acute Respiratory Failure, sponsored by University of Modena and Reggio Emilia. Recruiting at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-22.

Sponsored by University of Modena and Reggio Emilia · Observational

From the registry’s dates

  • Started Nov 2024; still recruiting 2 years later.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
325
Ages
18 Years and older
Sex
All
01

Study summary

This observational study aims to evaluate the relationship between clinical and physiological variables and the failure of non-invasive respiratory support (NIRS), including high-flow nasal oxygen (HFNO) and non-invasive ventilation (NIV), in patients with acute respiratory failure (ARF), both hypoxemic and/or hypercapnic. The study includes both retrospective and prospective components. Retrospective data will be collected from patient charts, while prospective data will be collected at defined time points during clinical care. The primary outcome is NIRS failure, defined as the need for orotracheal intubation. Secondary outcomes include in-hospital and 90-day mortality, ICU and hospital length of stay, and duration of non-invasive and invasive support.

02

Conditions studied

  • Acute Respiratory Failure

Keywords

  • Acute respiratory failure
  • High flow nasal cannula
  • Non-invasive ventilation
  • Inspiratory effort
03

In context

Lead sponsor

University of Modena and Reggio Emilia is the lead sponsor of 65 studies on the registry; 17 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients admitted to the Respiratory Disease Unit of the University of Modena and Reggio Emilia

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years
  • Hospitalization in the Respiratory Medicine Unit at AOU Policlinico di Modena
  • Acute respiratory failure (hypoxemic and/or hypercapnic) with PaO₂/FiO₂ \< 300 mmHg
  • Undergoing treatment with HFNO or NIV

Exclusion criteria

Exclusion Criteria:

  • Immediate need for invasive ventilation upon admission
  • Known neuromuscular disease
  • Pregnancy
  • Lack of
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
325 participants (estimated)
Patient registry
No

Interventions

  • OtherThis is an observational study. Interventions are standard of care and include: High-flow nasal oxygen (HFNO) Non-invasive ventilation (NIV) Pnose monitoring

    No experimental interventions are administered as part of the study.

06

What researchers measure

Primary outcomes

  1. Rate of failure of non-invasive respiratory support

    Number of patients experiencing NIRS failure (defined as escalation to another NIRS modality, need for orotracheal intubation, or death) over the total number of patients.

    Time frame: 30 days

Secondary outcomes

  1. Clinical impact

    Mortality

    Time frame: From enrollment to 90 days

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Nov 2024 (actual). Primary completion is estimated for Jan 2028, 38 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 24, 2025
First posted
May 25, 2025
StartActual
Nov 1, 2024
Primary completionEst.
Jan 1, 2028
CompletionEst.
Jan 1, 2030
Last update
Jan 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06989385
Lead sponsor
University of Modena and Reggio Emilia
Responsible party
Roberto Tonelli (Assistant Professor, University of Modena and Reggio Emilia) — Principal investigator
First posted
May 25, 2025
Start date
Nov 1, 2024
Primary completion
Jan 1, 2028 (estimated)
Completion
Jan 1, 2030 (estimated)
Last update
Jan 22, 2026

Study contacts

Roberto Tonelli, MD, PhD
Contact
rtonelli@unimore.it
+390594225934

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion